Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Comprehensive Loss (Unaudited)

v3.24.1.1.u2
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]    
Product Revenue
Product Cost of Sales
Gross Income
Administrative Expenses 1,068,320 987,987
Research and Development Expenses 1,198,938 770,430
Stock Based Compensation 517,365 69,068
Warrant Issuance Expenses 762,834
Loss from Operations (2,784,623) (2,590,319)
Other (Income) Expenses    
Interest and Dividend Income (18,306) (25,824)
Gain/Loss on Sale of Investments (175) (175)
FMV Change - Equity Investments 899 1,712
FMV Change - Derivatives (61,000) 120,700
FMV Change - Warrants 7,094,000 (1,175,000)
Total Other (Income) Expenses 7,015,418 (1,078,587)
Loss Before Income Tax (9,800,041) (1,511,732)
Income Tax Benefit
Net Loss (9,800,041) (1,511,732)
Preferred Stock Dividends 1,201,867 158,333
Net Loss Attributable to Common Stockholders $ (11,001,908) $ (1,670,065)
Net loss per common share - basic $ (5.14) $ (1.20)
Net loss per common share - diluted $ (5.14) $ (1.20)
Weighted average common shares outstanding - basic 2,141,131 1,392,210